Alliancebernstein L.P. Increases Stake in Amedisys, Inc. (NASDAQ:AMED)

Alliancebernstein L.P. grew its stake in shares of Amedisys, Inc. (NASDAQ:AMED) by 2.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 677,787 shares of the health services provider’s stock after purchasing an additional 13,587 shares during the quarter. Alliancebernstein L.P. owned approximately 2.07% of Amedisys worth $61,536,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in AMED. Blue Trust Inc. boosted its position in Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after buying an additional 124 shares during the period. HBW Advisory Services LLC bought a new position in shares of Amedisys during the fourth quarter valued at about $38,000. Versant Capital Management Inc boosted its holdings in shares of Amedisys by 68.5% during the fourth quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after purchasing an additional 183 shares during the period. Vestcor Inc bought a new stake in shares of Amedisys in the fourth quarter worth about $73,000. Finally, Venturi Wealth Management LLC grew its stake in shares of Amedisys by 397.4% in the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock worth $89,000 after purchasing an additional 779 shares during the last quarter. Institutional investors own 94.36% of the company’s stock.

Amedisys Stock Down 1.2 %

AMED stock opened at $91.89 on Friday. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The company has a market capitalization of $3.01 billion, a price-to-earnings ratio of 36.46, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76. The business’s 50 day moving average price is $92.31 and its two-hundred day moving average price is $92.32. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The firm had revenue of $598.05 million during the quarter, compared to analysts’ expectations of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. As a group, analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $101.00.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.